After finishing at $5.38 in the prior trading day, 2seventy bio Inc (NASDAQ: TSVT) closed at $4.72, down -12.27%. In other words, the price has decreased by -$0.6600 from its previous closing price. On the day, 3763303 shares were traded. TSVT stock price reached its highest trading level at $5.8500 during the session, while it also had its lowest trading level at $4.5600.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of TSVT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.98 and its Current Ratio is at 3.98. In the meantime, Its Debt-to-Equity ratio is 1.01 whereas as Long-Term Debt/Eq ratio is at 0.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on January 31, 2024, Upgraded its rating to Outperform and sets its target price to $18 from $5 previously.
Leerink Partners Downgraded its Outperform to Market Perform on October 30, 2023, while the target price for the stock was maintained at $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 05 ’24 when Leschly Nick sold 1,554 shares for $3.75 per share. The transaction valued at 5,833 led to the insider holds 1,085,476 shares of the business.
Baird William D III sold 1,380 shares of TSVT for $5,180 on Jan 05 ’24. The Chief Operating Officer now owns 161,335 shares after completing the transaction at $3.75 per share. On Jan 05 ’24, another insider, Gregory Philip D, who serves as the Chief Scientific Officer of the company, sold 795 shares for $3.75 each. As a result, the insider received 2,984 and left with 230,842 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSVT now has a Market Capitalization of 242.19M and an Enterprise Value of 281.87M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.38 while its Price-to-Book (P/B) ratio in mrq is 0.94. Its current Enterprise Value per Revenue stands at 2.81 whereas that against EBITDA is -1.37.
Stock Price History:
Over the past 52 weeks, TSVT has reached a high of $12.69, while it has fallen to a 52-week low of $1.53. The 50-Day Moving Average of the stock is 4.6991, while the 200-Day Moving Average is calculated to be 5.6536.
Shares Statistics:
The stock has traded on average 1.59M shares per day over the past 3-months and 1.05M shares per day over the last 10 days, according to various share statistics. A total of 50.63M shares are outstanding, with a floating share count of 47.18M. Insiders hold about 6.81% of the company’s shares, while institutions hold 94.77% stake in the company. Shares short for TSVT as of Feb 15, 2024 were 5.81M with a Short Ratio of 3.66, compared to 6.4M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.47% and a Short% of Float of 11.61%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.76 for the current quarter, with a high estimate of -$0.26 and a low estimate of -$0.95, while EPS last year was -$1.08. The consensus estimate for the next quarter is -$0.59, with high estimates of -$0.16 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$0.13 and -$3.28 for the fiscal current year, implying an average EPS of -$1.89. EPS for the following year is -$0.72, with 6 analysts recommending between $0.91 and -$1.59.
Revenue Estimates
6 analysts predict $16.88M in revenue for the current quarter. It ranges from a high estimate of $22.1M to a low estimate of $12.5M. As of the current estimate, 2seventy bio Inc’s year-ago sales were $22.3M, an estimated decrease of -24.30% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $19.21M, a decrease of -46.70% less than the figure of -$24.30% in the same quarter last year. There is a high estimate of $31.4M for the next quarter, whereas the lowest estimate is $9.77M.
A total of 8 analysts have provided revenue estimates for TSVT’s current fiscal year. The highest revenue estimate was $154.23M, while the lowest revenue estimate was $47.15M, resulting in an average revenue estimate of $91.74M. In the same quarter a year ago, actual revenue was $100.39M, down -8.60% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $115.44M in the next fiscal year. The high estimate is $213.22M and the low estimate is $57.61M. The average revenue growth estimate for next year is up 25.80% from the average revenue estimate for this year.
